Welcome to our dedicated page for ALLURION TECHNOLOGIES SEC filings (Ticker: ALUR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Allurion Technologies, Inc. filings document the company’s medical-device weight-loss business, securities, and public-company status. Recent Form 8-K reports cover FDA PMA approval for the Allurion Gastric Balloon System featuring the Allurion Smart Capsule, selected preliminary financial results, warrant exercise inducement agreements, and NYSE continued-listing notices affecting the company’s common stock and warrants.
The filing record also includes proxy and annual-meeting disclosures for board elections, auditor ratification, equity incentive plan amendments and other shareholder voting matters. Form 12b-25 reporting documents delayed quarterly-report timing, while capital-structure disclosures describe common stock, warrants, exercise prices, stockholder approval mechanics and beneficial-ownership limitations.
Allurion Technologies, Inc. filed a notice of late filing for its Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, explaining that it needed extra time to prepare and review items that occurred after quarter end. That work is now complete, and the company expects to file the Form 10-Q on the date of this notice, within the five-day extension allowed.
Allurion expects to report total revenue of approximately $2.7 million for the three months ended September 30, 2025, compared with approximately $5.4 million a year earlier. Gross profit is expected to be about $1.3 million versus $3.1 million, with lower operating expenses: sales and marketing of about $3.1 million, research and development of about $2.0 million, and general and administrative of about $5.8 million. Loss from operations is expected to be approximately $9.6 million, improved from approximately $12.3 million in the prior-year quarter.
Allurion Technologies, Inc. (ALUR) reported a Form 4 showing that funds managed by RTW Investments, LP acquired common stock and accompanying warrants in a private placement. The reporting entities bought blocks of 991,544, 767,848 and 96,896 shares of common stock, each with matching warrants, at a purchase price of $1.67 per share and accompanying warrant. Following these transactions, the funds report beneficial ownership of up to 3,138,798, 2,427,089 and 298,992 shares through different RTW-managed vehicles, plus an additional 26,551 shares in another fund. The warrants carry an exercise price of $1.67 per share, become exercisable only after stockholder approval, and expire five years after that approval. Each warrant is subject to a beneficial ownership cap of 4.99% (or 9.99% at the holder’s election), and Allurion has agreed to use its reasonable best efforts to hold a stockholder meeting no later than January 31, 2026 to seek approval for the warrant share issuance.
Allurion Technologies (ALUR): RTW Investments and affiliates filed an amended Schedule 13D disclosing 48.1% beneficial ownership, or 5,891,430 shares, based on 12,249,232 shares outstanding upon the private placement closing.
On November 11, 2025, RTW agreed to exchange remaining note principal, $48.0 million under a 2023 revenue interest financing agreement and $9.5 million under a 2024 agreement for Series B convertible preferred stock. The preferred has an 8.25% dividend, is convertible at $3.37 per share of common stock, and includes a 9.9% beneficial ownership conversion cap. Closing is subject to stockholder approval and listing/effectiveness conditions.
RTW funds also bought 1,856,288 shares with accompanying warrants at $1.67 per unit for approximately $3.1 million. Governance terms allow RTW to nominate one or two directors while it holds at least 10% or 30% of the Company’s securities, respectively, with additional nomination rights upon a specified breach tied to a $3.0 million minimum cash balance and FDA marketing authorization by December 31, 2026.
Allurion Technologies, Inc. has an effective prospectus covering the resale of up to 65,211,325 shares of common stock, and this supplement adds details from a new current report. The company agreed to a $5 million private placement of 2,994,012 common shares and accompanying warrants at $1.67 per share and warrant, with the warrants exercisable after stockholder approval of the underlying shares, which the company must seek by January 31, 2026.
Allurion also signed an exchange agreement with RTW to swap all amounts outstanding under certain convertible notes and two revenue interest financing agreements for newly created Series B convertible preferred stock with a stated value of $1,000 per share, an 8.25% annual dividend, and a conversion price of $3.37 per share, subject to a 9.9% ownership cap. The Series B ranks senior to common stock, carries voting and board nomination rights tied to RTW’s ownership and covenant compliance, and requires the company to maintain at least $3 million in unrestricted cash and obtain FDA marketing authorization for a product by December 31, 2026. Separately, RTW recently converted about $5 million of notes into 1,492,539 common shares at $3.35 per share.
Allurion Technologies (ALUR) announced two financing moves. The company agreed to a private placement of 2,994,012 common shares with accompanying warrants to purchase up to 2,994,012 shares, for an aggregate purchase price of about $5 million at $1.67 per share and warrant. The warrants are exercisable after stockholder approval at an exercise price of $1.67 and expire five years after approval, with a beneficial ownership cap of 4.99% (or 9.99% at the holder’s election). A resale registration is targeted to be filed by January 10, 2026; Roth Capital Partners will receive a 7% cash fee on gross proceeds and up to $100,000 in expenses.
Separately, Allurion agreed with RTW to exchange its outstanding notes and obligations under two revenue interest financing agreements for newly created Series B convertible preferred stock, subject to stockholder approval no later than January 31, 2026. Each preferred share has a $1,000 stated value, accrues 8.25% dividends, and is convertible at $3.37 per share (subject to adjustment) with a 9.9% beneficial ownership limit. In a related step, on November 4–5, 2025, RTW converted approximately $5 million of notes at the floor conversion price of $3.35, receiving 1,492,539 common shares.
Allurion Technologies (ALUR): RTW files Amendment No. 9 to Schedule 13D, reporting beneficial ownership of 4,035,142 shares, or 43.6% of the common stock.
On November 5, 2025, the RTW funds converted $5.0 million principal amount of notes into 1,492,539 shares under an amended note purchase agreement. The ownership percentages are based on 7,762,681 shares outstanding as of August 8, 2025, plus the shares issued pursuant to the November 2025 conversion notice. RTW Investments, LP and Roderick Wong report shared voting and dispositive power over 4,035,142 shares.
By entity, RTW Master Fund, Ltd. reports 2,147,254 shares (23.2%), and RTW Innovation Master Fund, Ltd. reports 1,659,241 shares (17.9%). The notes include a 9.99% beneficial ownership conversion cap, while RTW’s warrants are subject to a 4.99% blocker that can be increased to 9.99% with 61 days’ prior notice.
Allurion Technologies (ALUR): Affiliated funds managed by RTW Investments reported converting an aggregate $5.0 million principal amount of Allurion’s convertible senior secured notes into common stock at the floor conversion price of $3.35 per share on November 5, 2025. The filing identifies the reporting persons as a Director and 10% owner and indicates the form is filed by more than one reporting person.
The conversion resulted in share issuances to multiple RTW-managed entities, including 822,722 shares to RTW Master Fund and 631,954 shares to RTW Innovation. The notes bear 6.0% annual interest and mature on April 16, 2031. Remaining notes are convertible at $40.50 per share and may also be converted at additional prices at the issuer’s discretion. A 9.99% beneficial ownership limitation applies, unless a discretionary conversion is used.
Allurion Technologies, Inc. reported that Milena Alberti-Perez, a Class III director and chairperson of the Audit Committee, resigned from the board effective September 30, 2025. The company states that her resignation was not due to any disagreement with management, the board, or company operations, policies, or practices.
The filing explains that Ms. Alberti-Perez is stepping down to focus on opportunities in the media sector, including a new board role at another public company. Following her departure, the size of Allurion’s board will be reduced from nine to eight members as part of the board’s view that a smaller board can improve efficiency and reduce director compensation costs. The board is evaluating which current director will be appointed as the new Audit Committee chairperson.
Allurion Technologies amended its quarterly report to reflect a restatement and adjustments tied to a Reverse Stock Split and the closing of its Business Combination with Compute Health. The filing discloses material weaknesses in internal control over financial reporting and describes remediation steps including hiring accounting staff, implementing a new ERP, and engaging a national accounting firm.
The company completed several financing and capital transactions: a PIPE investment of $37.9 million, a Public Offering consummated July 1, 2024, amended convertible note arrangements, and revenue interest financing that pays 6.0% of annual net sales through 2026 and up to 10.0% thereafter until 2030. The Allurion Balloon sales were suspended in France and remediation is underway; the company also disclosed NYSE non-compliance and submitted a plan to regain compliance.
Allurion Technologies amended its quarterly report to reflect a restatement and adjustments tied to a Reverse Stock Split and the closing of its Business Combination with Compute Health. The filing discloses material weaknesses in internal control over financial reporting and describes remediation steps including hiring accounting staff, implementing a new ERP, and engaging a national accounting firm.
The company completed several financing and capital transactions: a PIPE investment of $37.9 million, a Public Offering consummated July 1, 2024, amended convertible note arrangements, and revenue interest financing that pays 6.0% of annual net sales through 2026 and up to 10.0% thereafter until 2030. The Allurion Balloon sales were suspended in France and remediation is underway; the company also disclosed NYSE non-compliance and submitted a plan to regain compliance.
Allurion Technologies amended its Form 10-Q to restate prior interim financials and reflect a 1-for-25 reverse stock split effective January 3, 2025. The filing discusses the completed Business Combination with Compute Health and conversion/recapitalization mechanics that produced Allurion common stock and warrants, notes the Company completed a Public Offering on July 1, 2024, and records a $37.9 million PIPE investment. The company discloses material weaknesses in internal control over financial reporting and remediation actions underway, and reports a suspension of Allurion Balloon sales in France in August 2024. Debt and convertible note amendments, warrant conversions and derivative accounting for certain PIPE and conversion options are described.
Allurion Technologies amended its Form 10-Q to restate prior interim financials and reflect a 1-for-25 reverse stock split effective January 3, 2025. The filing discusses the completed Business Combination with Compute Health and conversion/recapitalization mechanics that produced Allurion common stock and warrants, notes the Company completed a Public Offering on July 1, 2024, and records a $37.9 million PIPE investment. The company discloses material weaknesses in internal control over financial reporting and remediation actions underway, and reports a suspension of Allurion Balloon sales in France in August 2024. Debt and convertible note amendments, warrant conversions and derivative accounting for certain PIPE and conversion options are described.